Last updated on November 2017

DECLARE -Dapagliflozin Effect on CardiovascuLAR Events - A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients with Type 2 Diabetes


Brief description of study

DECLARE -Dapagliflozin Effect on CardiovascuLAR Events - A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients with Type 2 Diabetes

Detailed Study Description

The primary efficacy objective is to determine whether treatment with dapagliflozin compared with placebo when added to current background therapy will result in a reduction in the incidence of the composite endpoint of cardiovascular death, myocardial infarction (MI), or ischemic stroke in patients with type 2 diabetes mellitus (T2DM) with either established cardiovascular disease or at least two cardiovascular risk factors in addition to T2DM.

Clinical Study Identifier: TX81271

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Wendy Schneider, MSN

Holy Cross Jim Moran Heart and Vascular Research Institute
Coral Springs, FL USA
  Connect »